Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram
- PMID: 3760368
- DOI: 10.1016/s0735-1097(86)80440-5
Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram
Abstract
Programmed ventricular stimulation and ambulatory electrocardiography were performed both before and during oral sotalol therapy in 39 patients with ventricular tachyarrhythmia inducible by programmed stimulation (sustained ventricular tachycardia [n = 31], ventricular fibrillation [n = 3], nonsustained ventricular tachycardia [n = 5]). Oral sotalol was started at 80 mg twice daily and the dose thereafter was then gradually increased until a mean daily dose of 300 mg (range 160-480) was reached. In 12 of 34 patients with inducible sustained ventricular tachycardia or fibrillation the arrhythmia was suppressed; in 19 patients it was not and in 3 the spontaneous arrhythmia recurred. Reproducibly inducible nonsustained ventricular tachycardia was suppressed by sotalol in all five patients with this arrhythmia. Thus, a favorable electrophysiologic response was obtained in 17 (44%) of 39 patients. Arrhythmia suppression correlated with the type of arrhythmia (unsustained or sustained) induced during the control period (p less than 0.05), and nonresponders had a higher incidence of previously ineffective drug trials (p less than 0.05). In 22 patients treated long term with sotalol suppression of arrhythmia inducibility on programmed stimulation predicted freedom from recurrences (16 of 17), whereas continued inducibility indicated drug failure (5 of 5) (p less than 0.005). Serial ambulatory electrocardiograms performed in 37 of the 39 patients did not correlate with the results of electrophysiologic testing. For the patients on long-term treatment, invasive testing was superior to electrocardiographic monitoring in predicting outcome. These data indicate that in daily doses of 160 to 480 mg oral sotalol is a very useful agent in patients presenting with sustained ventricular tachycardia or fibrillation, and its efficacy is fairly well predicted by programmed stimulation.
Similar articles
-
Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs.Am J Cardiol. 1988 May 1;61(13):1012-7. doi: 10.1016/0002-9149(88)90117-8. Am J Cardiol. 1988. PMID: 3129926 Clinical Trial.
-
Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts.Am J Cardiol. 1989 Jul 1;64(1):33-6. doi: 10.1016/0002-9149(89)90648-6. Am J Cardiol. 1989. PMID: 2741811
-
Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up.Eur Heart J. 1989 Mar;10(3):218-26. doi: 10.1093/oxfordjournals.eurheartj.a059469. Eur Heart J. 1989. PMID: 2707270
-
Electrophysiologic evaluation of antiarrhythmic therapy for ventricular tachyarrhythmias.Am J Cardiol. 1988 Oct 19;62(12):39H-45H. doi: 10.1016/0002-9149(88)90339-6. Am J Cardiol. 1988. PMID: 3052008 Review.
-
Electrocardiographic predictors in the ESVEM trial: unsustained ventricular tachycardia, heart period variability, and the signal-averaged electrocardiogram.Prog Cardiovasc Dis. 1996 May-Jun;38(6):463-88. doi: 10.1016/s0033-0620(96)80011-9. Prog Cardiovasc Dis. 1996. PMID: 8638028 Review.
Cited by
-
The role of EP-guided therapy in ventricular arrhythmias: beta-blockers, sotalol, and ICD's.J Interv Card Electrophysiol. 2000 Jan;4 Suppl 1:57-63. doi: 10.1023/a:1009822313578. J Interv Card Electrophysiol. 2000. PMID: 10590490 Review.
-
Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance.Drugs. 1991 May;41(5):672-701. doi: 10.2165/00003495-199141050-00002. Drugs. 1991. PMID: 1712704 Review.
-
Sotalol in patients with life-threatening ventricular tachyarrhythmias.Cardiovasc Drugs Ther. 1990 Oct;4(5):1425-32. doi: 10.1007/BF02018271. Cardiovasc Drugs Ther. 1990. PMID: 2278875
-
Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.Drugs. 1993 Oct;46(4):678-719. doi: 10.2165/00003495-199346040-00007. Drugs. 1993. PMID: 7506652 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources